OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 12, 2023
Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.
Webinar Date/Time: Wed, May 24, 2023 2:00 PM EDT
May 04, 2023
Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.
May 03, 2023
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
The use of smart tools in early drug discovery can have an impact on downstream phases of drug development.
The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.
Competition in the organ-on-a-chip market increases as NETRI enters the arena.
May 02, 2023
Process control is essential for using continuous hot-melt extrusion to enhance solubility.
Digital transformation to the Pharma 4.0 paradigm moves forward in process development and clinical and commercial manufacturing.
In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.